Evaluation of the treatment response on hepatocellular carcinoma with locoregional and/or systemic therapy by multi-modality imaging and artificial intelligence

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100054671

Enrollment

Unknown

Registered

2021-12-23

Start date

2022-01-10

Completion date

Unknown

Last updated

2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Gold Standard:Biopsy pathological dignose

Index test:Sensitivity,&#32

specificity,&#32

accuracy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years and diagnosed with hepatocellular carcinoma by surgery or biopsy; 2. Agree to perform two-dimensional ultrasound, elastography and contrast-enhanced ultrasound within one week before local treatment or systemic treatment and 4-6 weeks after treatment, and complete liver enhanced CT/MRI examination 4-6 weeks after treatment; 3. Child-Pugh A or B liver function.

Exclusion criteria

Exclusion criteria: 1. The image is missing; 2. Those with underlying diseases such as serious heart disease and kidney disease.

Design outcomes

Primary

Measure	Time frame
sensitivity;specificity;	—

Countries

China

Contacts

Public ContactWang Wei

The First Affiliated Hospital of Sun Yat-Sen University

wangw73@mail.sysu.edu.cn+86 87765183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026